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Objetivos: La presente investigación se refiere a la preparación y caracterización de complejos de 
rufinamida HP-β-ciclodextrina preparados por el método de amasado.
Material y métodos: La rufinamida fue donada por la empresa Torrent Pharmaceuticals limitado. HP-
β-ciclodextrina (HP-β-CD) se adquirió de Himedia, India. Metanol y ácido clorhídrico se obtuvieron 
de SD Fine Chem. SA. Ltd., India. Se utilizó el método de amasado para preparar complejos de 
inclusión de rufinamida. El estudio de la fase de solubilidad se realizó para comprobar la formación 
de complejos de inclusión. Los complejos preparados se caracterizaron por diferentes métodos como 
DSC, FTIR, X-RPD y ensayo de disolución in vitro.
Resultados: Se encontró que se producían formación de complejos en la relación 1:1. La constante de 
estabilidad encontrada fue de 221,27 M-1. Los estudios de DSC, FTIR confirmaron la formación del 
complejo de inclusión. Mediante X-RPD se confirmó la naturaleza amorfa del complejo.
Conclusiones: El estudio de disolución in vitro mostró que la proporción 1:1.5 liberaba alrededor de 
50% de fármaco en 30 min y a los 60 minutos se consiguió una liberación del 70%.
PALABRAS CLAVE: Hidroxi propil β-ciclodextrina, método de amasado, rufinamida, DSC, FTIR, 
X-RPD.
ABSTRACT 
Aims: The present investigation concerns the preparation and characterization of Rufinamide HP-β-
cyclodextrin complexes prepared by the kneading method. 
Material & methods: Rufinamide was procured as a gift sample from Torrent Pharmaceuticals 
limited. HP-β-cyclodextrin (HP-β-CD) was purchased from Himedia, India. Methanol and 
Hydrochloric Acid were purchased from S. D. Fine Chem. Pvt. Ltd., India. kneading method was 
selected to prepare inclusion complexation of Rufinamide. Phase solubility study was performed to 
check formation of inclusion complex. Prepared complex were characterize by different methods like 
DSC study, FTIR study, X-RPD study & in-vitro dissolution study 
Results: It was found that there is a formation of 1:1 inclusion complex between HP-β-CD as stability 
constant was found to be 221.27 M-1. DSC study, FTIR study had given supporting data for formation 
of inclusion complex. Amorphous nature of the complex was confirmed from the X-RPD study. 
Conclusions: From in-vitro dissolution study it was found that 1:1.5 complex showed around 50% 
drug released in 30 min & more than 70% of Drug release in 60 mins. 
KEY WORDS: Cyclodextrins, Differential Scanning Colorimetry, Hydroxy propyl β-cyclodextrin, 
kneading Method, Rufinamide
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INTRODUCTION
Rufinamide (RUF) [1-(2, 6-diflurophenyl) methyl-1H-1, 
2, 3-triazole-4-carboxamide] is a triazole compound and 
has a chemical formula of C10H8F2N4O. In experimental 
models, RUF has been shown to modulate sodium 
channels, prolonging their inactivation phase, thereby 
limiting the firing of sodium-dependent action potentials 
in neurons, and resulting in a membrane stabilizing 
effect.1, 2 However, it’s very low aqueous solubility around 
40 mg/L3 and poor dissolution can cause formulation 
problems and limit its therapeutic application by delaying 
the rate of absorption and the onset of action.(2)  Solid 
dispersions of Rufinamide were reported using HPMC by 
solvent evaporation method for improving dissolution.(4) 
Cyclodextrins are commonly used in drug formulations as 
solubility enhancers because of their ability to form water 
soluble inclusion complexes with poorly water soluble 
drugs.(5) The method of complexation may play a role in 
drug solubilization.(6) Therefore, it seemed of interest to 




Rufinamide drug was procured as a gift sample from 
Torrent Pharmaceutical Ltd., India.  HP-β-cyclodextrin 
(HP-β-CD) was purchased from Himedia, India. Methanol 
and Hydrochloric Acid were purchased from S. D. Fine 
Chem. Pvt. Ltd., India.
Calibration Curve
1 mg/ml stock solution of drug was prepared in methanol. 
All further dilutions to make 50, 75, 100, 125, 150 µg/ml 
standard solutions were made by 0.1N HCl. The spectra 
of the standard solutions were recorded using UV Visible 
spectrophotometer for 200nm to 400nm range against 
0.1N HCl as blank. The observations were recorded in 
triplicate.
Phase solubility studies
An excess of drug was added to 5 mL of HP-β-CD aqueous 
solutions (5–25 Mmol) in 10-mL stoppered conical flasks and 
shaken at room temperature in an orbital shaker incubator.
(7) At equilibrium after 48 hours, aliquots were withdrawn, 
filtered (0.22 μm pore size, Whatman) and assayed for drug 
content at 262.0 nm using uv visible spectrophotometer 
(UV-1800, Shimadzu, Japan). The apparent 1:1 stability 
constant of the Rufinamide-cyclodextrin complex was 
calculated from the phase-solubility diagram:
where Kc is the stability constant (L mol–1), slope is obtained 
from the linear /relationship between the concentration of 
Rufinamide and HP-β-CD and S0 is aqueous solubility of 
Rufinamide (mmol–1 L).
Preparation of physical mixtures and the solid inclusion 
complex
For physical mixtures, RUF and HP-β-CD were weighed 
accurately at a 1:1 molar ratio, mixed thoroughly by 
trituration in a mortar and sieved through 0.25 mm sieve. 
All physical mixtures were stored in dessicator until 
further evaluation. The inclusion complex of Rufinamide 
with HP-β-CD was prepared at a 1:1 molar ratio by wetting 
the physical mixture in a mortar with a minimum volume 
of ethanol/water (1:1, by volume) mixture and kneading 
thoroughly for 60 min with a pestle to obtain a paste, which 
was then dried under tray drier at 50ºC, sieved through 
0.25 mm sieve and stored in a dessicator until further 
evaluation.
Dissolution studies(8, 9)
Dissolution studies were performed in 0.1 N HCl (pH 
1.2, 900 mL) at 37 ± 0.2 °C, using USP XXIII apparatus 
(Electrolab, India) with a paddle rotating at 50 rpm. Solid 
products, each containing 100 mg of drug, were subjected 
to dissolution. At fixed time intervals (5, 10, 15, 30, 45 and 
60 minutes), withdrawn samples were filtered (Whatman 
filter paper No. 41) and assayed for drug content at 
262.0 nm using uv visible spectrophotometer (UV-1800, 
Shimadzu, Japan). 
Differential scanning calorimetry (DSC)(10)
DSC thermograms of the drug, cyclodextrin, physical 
mixture and kneaded complex were recorded on a Perkin 
Elmer 1/ DSC equipment, Massachusetts, USA. The 
instrument was calibrated with indium and zinc prior 
to analyzing the samples under nitrogen. All accurately 
weighed samples (2.5 mg) were placed into sealed 
aluminium pans and scanned at the heating rate of 10 
◦Cmin−1 over the temperature range of 30–240 ◦C.  
X-ray Diffractometry(11)
X-ray powder diffraction patterns were recorded using D2 
Phaser, BRUKER, AXS Inc. Germany at 40mV, 45 kV and 
with monochromatized Cu Kα radiation (λ = 1.54056Å). 
The samples were scanned at room temperature in the 
continuous scan mode over the 100–800 range.
RESULTS AND DISCUSSION
Preliminary studies
The Complexation of Rufinamide with HP-β-CD was 
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prepared by the kneading method and were characterized 
by DSC, FTIR and X-RAY Diffraction studies.
All complexes showed increased dissolution efficiency, 
reduced time required for 50% drug to be dissolved higher 
dissolution (> 50% released in 30 min) was obtained using a 
1:1.5 molar ratio of the drug to HP-β-CD. Therefore further 
investigations were carried out for the 1:1.5 molar ratios.
Figure 1: UV spectra & Calibration curve of drug in 0.1N HCl. 
Phase solubility curve












0 5 10 15 20 25 30













Figure 2. Phase solubility Diagram
Calibration Curve
The drug spectra (Figure 1-A) showed a prominent peak 
at 262 nm which indicates that trace amount of methanol 
did not interfere in absorption. It was concluded that the 
ranges of absorbance lies in ranges of 0.2 to 0.8 and hence 
it follows Lambert’s beers law. The R2 value was found to 
be 0.9991 (Figure 1-B).
Phase solubility
Rufinamide is a practically insoluble drug. The solubility of 
rufinamide in distilled water at room temperature was 32.0 
mg/L and was notably affected by the presence of HP-β-
CD. The solubility of rufinamide is linearly increases with 
increase in the concentration of HP-β-CD from 0-25 mmol 
concentration. The obtained phase solubility diagram 
was linear (Figure 2) and could be classified as AL type 
according to Higuchi and Connors. The slope of solubility 
diagram was less than one; it was therefore assumed that 
the solubility increase could be attributed to the formation 
of the 1:1 complex. Stability constant value obtained for the 
% DRUg RELEASE [AVERAgE ± S.D. (N=3)]
Time (min) Pure Drug Complex (1:1) Complex (1:1.5) Complex (1:2)
5 12.20±0.66 24.69±3.67 27.13±4.62 28.73±5.55
10 14.84±1.08 31.08±4.66 34.78±5.66 31.13±5.67
15 15.62±0.86 38.16±7.44 40.68±6.56 48.00±7.55
30 16.28±0.49 45.92±9.36 50.92±4.80 53.42±5.71
45 18.29±0.68 54.99±6.72 60.65±5.84 57.68±3.94
60 18.79±0.50 66.00±5.95 74.17±4.92 69.93±4.92
Table 1: Comparison of results of dissolution of pure drug with inclusion complex
A: UV spectra of drug; B: Calibration curve of drug in 0.1N HCl
Patel Ravish J, Dave Dhara A.
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Figure 3: Comparison of dissolution profile of pure drug with complexes
Rufinamide-HP-β-CD complex was 221.27 M–1 which well 
within the ideal range of 100 M–1 to 1000 M–1. The Kc value 
indicated that the Rufinamide-HP-β-cyclodextrin complex 
at a 1:1 ratio is adequately stable.
Dissolution study
The in vitro dissolution profiles of the pure drug and 
inclusion complex of 1:1, 1:1.5 &1:2 ratios were shown in 
figure 3. The dissolution of complexes was higher compared 
to the drug alone. The dissolution profile of the kneaded 
complex 1:1.5 molar ratio showed 74.17% drug released in 
60 min while the pure drug showed 18.79% (Table 1). This 
enhancement can be attributed to the higher hydrophilic 
character of the systems due to the presence of the carrier, 
which can reduce the interfacial tension between the poorly 
water soluble drug and the dissolution medium.
Moreover, in the case of HP-β-CD, in the early stage of 
the dissolution process, the carrier dissolves more rapidly 
than the drug. Hence, it can act on the hydrodynamic layer 
surrounding the drug particles, resulting in an in situ 
inclusion process that improves the dissolution of the drug. 
Figure 4: DSC thermogram of pure drug, HP-β-CD & Physical mixture & complex.
A: Rufinamide Drug; B: HP-β-CD; C: Drug: HP-β-CD (1:1) physical mixture, D: Drug: HP-β-CD(1:1) Complex; E: Drug: HP-β-CD(1:1.5) Complex
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In fact, the systems containing a larger amount of HP-β-
CD showed faster drug dissolution. As shown above, the 
kneaded complex showed 4 time higher dissolution in 60 
min than that of pure drug.
DSC study
DSC curves of the pure drug, HP-β-CD, physical mixture, 
1:1, 1:1.5, 1:2 molar kneaded complex are shown in figure 
4. DSC curve of the drug showed a sharp endothermic 
peak at 242.38°C the sharp melting peak of rufinamide was 
shifted towards 200.31ºC, 201.74ºC in case of 1:1 & 1:1.5 
respectively. Shifting of HP-β-CD peak towards 89.32ºC, 
83.09ºC of 1:1 & 1:1.5 respectively, this was a deviation 
from 75.32ºC of pure HP-β-CD. So this change indicates 
formation of inclusion complex. 
X-RAY Diffraction Study 
From the X-RD data it was cleared that the drug was 
in crystalline state it was confirmed from the angle of 
diffraction because peak position is an indication of crystal 
structure in which peak height is a measure of crystallanity. 
Diffractogram of pure drug exhibited characteristic intense 
peaks at 2Ɵ value of 10º to 30 º.  They were reduced after 
inclusion Complexation formation with HP-β-CD prepared 
by kneading method. So it is indicating of amorphous state 
of a pure drug. This was the confirmation of the change in 
state of rufinamide. So this might be a reason for increase in 
the solubility of rufinamide after inclusion Complexation.
CONCLUSIONS
The dissolution profile of the kneaded complex (1:1.5 
molar ratio) showed more than 70% drug released in 60 
min. Further study is required to prepare a prompt release 
oral formulation of rufinamide by utilizing this complex.
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